LifeCycle Pharma to collaborate with three global pharmaceutical companies

Published: 12-Oct-2006

Danish company LifeCycle Pharma has entered into three strategic collaboration agreements with leading players in the pharmaceutical industry: Sandoz (an affiliate of Novartis), Merck Generics (a subsidiary of Merck KGaA) and H. Lundbeck.


Danish company LifeCycle Pharma has entered into three strategic collaboration agreements with leading players in the pharmaceutical industry: Sandoz (an affiliate of Novartis), Merck Generics (a subsidiary of Merck KGaA) and H. Lundbeck.

'These new partnerships provide a strong validation of our innovative MeltDose technology, which improves the bioavailability of drugs with low water solubility,' said Dr Flemming Ørnskov, president and ceo of LifeCycle Pharma. 'We are now also a significant step closer to the first commercial launch of a product derived from LifeCycle Pharma's strong research and development pipeline.'

Sandoz and LifeCycle Pharma have entered into an exclusive development and commercialisation agreement regarding the US market with respect to an undisclosed fenofibrate product developed by LifeCycle Pharma. The parties will be jointly responsible for the future development and Sandoz will be solely responsible for later commercialisation of the product in the US. LifeCycle Pharma will receive milestone payments and a significant double-digit royalty rate on future sales. In 2005, the US market for fenofibrate products exceeded US$1bn.

The agreement with Merck Generics is similar and covers the European markets. Merck Generics is currently considering when to initiate the pivotal studies in Europe with the fenofibrate product. In 2005, the European market for fenofibrate products amounted to $235m.

Lundbeck has been granted rights to LifeCycle Pharma's MeltDose technology in connection with Lundbeck's further development of two internal pre-clinical CNS-related projects. LifeCycle Pharma will receive milestone payments related to achieved results in the future developments of these projects. Due to the nature of an existing agreement between Lundbeck and LifeCycle Pharma, LifeCycle Pharma will not receive royalties on future possible revenues of these two CNS-related projects.

See more

You may also like

Media

Domain Therapeutics receives $125m to assign its intellectual property

Read more
Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Media

Domain Therapeutics receives $125m to assign its intellectual property

Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Moving to continuous processes

As both the regulators and equipment manufacturers push the concept of continuous manufacturing, the mindset is filtering down from research and API production to finished products. But are all the requirements in place to make it successful? Susan Birks reports
Finance

Lundbeck embarks on another restructuring to drive profit and ensure growth

Will cut around 1,000 jobs in Europe
Media

Alzheimer’s treatment market value to exceed US$13bn by 2023

Rising prevalence, advances in diagnostic capability and greater awareness will drive growth
Finance

Lundbeck to buy Chelsea Therapeutics for US$658m

Danish company gains rights to FDA-approved Northera for the treatment of neurological disorders
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Finance

New products drive growth at Lundbeck in 2013

Received five approvals from US and European regulators
Subscribe now